Targovax asa and agenus announce collaboration on mutant kras cancer vaccine adjuvanted with qs-21 stimulon™

Lexington, mass., march 07, 2022 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, and targovax asa (ose: trvx), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that they have entered into a clinical collaboration and supply agreement to combine targovax's tg mutant kras cancer vaccines with agenus´s clinically validated and fda approved qs-21 stimulon adjuvant.
AGEN Ratings Summary
AGEN Quant Ranking